Evaluation of a multicomponent intervention consisting of education and feedback to reduce benzodiazepine prescriptions by general practitioners: The BENZORED hybrid type 1 cluster randomized controlled trial
Open accessThe DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
Abstract
Background: Current benzodiazepine (BZD) prescription guidelines recommend short-term use to minimize the risk of dependence, cognitive impairment, and falls and fractures. However, many clinicians overprescribe BZDs and chronic use by patients is common. There is limited evidence on the effectiveness of interventions delivered by general practitioners (GPs) on reducing prescriptions and long-term use of BZDs. We aimed to evaluate the effectiveness of a multicomponent intervention for GPs that seeks to reduce BZD prescriptions and the prevalence of long-term users. Methods and findings: We conducted a multicenter two-arm, cluster randomized controlled trial in 3 health districts in Spain (primary health centers [PHCs] in Balearic Islands, Catalonia, and Valencian Community) from September 2016 to May 2018. The 81 PHCs were randomly allocated to the intervention group (n= 41; 372 GPs) or the control group (n= 40; 377 GPs). GPs were not blinded to the allocation; however, pharmacists, researchers, and trial statisticians were blinded to the allocation arm. The intervention consisted of a workshop about the appropriate prescribing of BZDs and tapering-off long-term BZD use using a tailored stepped dose reduction with monthly BZD prescription feedback and access to a support web page. The primary outcome, based on 700 GPs (351 in the control group and 349 in the intervention group), compared changes in BZD prescriptions in defined daily doses (DDDs) per 1,000 inhabitants per day after 12 months. The 2 secondary outcomes were the proportion of long-term users (≥6 months) and the proportion of long-term users over age 65 years. Intention-to-treat (ITT) analysis was used to assess all clinical outcomes. Forty-nine GPs (21 intervention group and 28 control group) were lost to follow-up. However, all GPs were included in the ITT analysis. After 12 months, there were a statistically significant decline in total BZD prescription in the intervention group compared to the control group (mean difference: −3.24 DDDs per 1,000 inhabitants per day, 95% confidence interval (CI): −4.96, −1.53,p< 0.001). The intervention group also had a smaller number of long-term users. The adjusted absolute difference overall was −0.36 (95% CI: −0.55, −0.16,p> 0.001), and the adjusted absolute difference in long-term users over age 65 years was −0.87 (95% CI: −1.44, −0.30,p= 0.003). A key limitation of this clustered design clinical trial is the imbalance of some baseline characteristics. The control groups have a higher rate of baseline BZD prescription, and more GPs in the intervention group were women, GPs with a doctorate degree, and trainers of GP residents. Conclusions: A multicomponent intervention that targeted GPs and included educational meeting, feedback about BZD prescriptions, and a support web page led to a statistically significant reduction of BZD prescriptions and fewer long-term users. Although the effect size was small, the high prevalence of BZD use in the general population suggests that large-scale implementation of this intervention could have positive effects on the health of many patients. Trial registration: ISRCTN ISRCTN28272199.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Education on BZD prescribing and tapering, with monthly feedback on their BZD prescribing rate compared to other local clinicians, has been shown to lead to a reduction in BZD prescriptions and fewer patients taking BZDs long-term.201”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [201]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Damschroder, L. J., Aron, D. C., Keith, R. E., Kirsh, S. R., Alexander, J. A., & Lowery, J. C. (2009) · Implementation Science · doi:10.1186/1748-5908-4-50 · Cited by 14,496 · cited 2×
“Some authors suggest that blending of the effectiveness and implementation stages during development of an intervention could improve the translation of the research findings into clinical practice [42,43].”
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792 · cited 1×
“Missing outcomes were accounted for using multiple imputation with chained equation [47] to estimate DDDs per 1,000 inhabitants per day from GPs lost to follow-up.”
Kluger, A. N., & DeNisi, A. (1996) · Psychological Bulletin · doi:10.1037/0033-2909.119.2.254 · Cited by 5,882
Audit and feedback: effects on professional practice and healthcare outcomes
Ivers, N., Jamtvedt, G., Flottorp, S., Young, J. M., Odgaard-Jensen, J., French, S. D., O'Brien, M. A., Johansen, M., Grimshaw, J., & Oxman, A. D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000259.pub3 · Cited by 5,485 · cited 3×
“However, there was wide variation in their impact and the extent to which they were implemented [40,41].”
Curran, G. M., Bauer, M., Mittman, B., Pyne, J. M., & Stetler, C. (2012) · Medical Care · doi:10.1097/mlr.0b013e3182408812 · Cited by 4,058
Consort 2010 statement: extension to cluster randomised trials
Campbell, M. K., Piaggio, G., Elbourne, D. R., Altman, D. G., & for the CONSORT Group (2012) · BMJ · doi:10.1136/bmj.e5661 · Cited by 3,510 · cited 1×
“…analysis was used to assess all clinical outcomes, and the results are reported in accordance with the Consolidated Standards of Reporting Trials guidelines extension for cluster trials (S1 CONSORT Checklist) [48] and the Template for intervention Description and Replication (S1 TIDieR Checklist).”
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15767 · Cited by 3,163
A conceptual framework for implementation fidelity
Carroll, C., Patterson, M., Wood, S., Booth, A., Rick, J., & Balain, S. (2007) · Implementation Science · doi:10.1186/1748-5908-2-40 · Cited by 2,559
Knowledge translation of research findings
Grimshaw, J. M., Eccles, M. P., Lavis, J. N., Hill, S. J., & Squires, J. E. (2012) · Implementation Science · doi:10.1186/1748-5908-7-50 · Cited by 2,407
Forsetlund, L., Bjørndal, A., Rashidian, A., Jamtvedt, G., O'Brien, M. A., Wolf, F. M., Davis, D., Odgaard-Jensen, J., & Oxman, A. D. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003030.pub2 · Cited by 1,849
Educational outreach visits: effects on professional practice and health care outcomes
O'Brien, M. A., Rogers, S., Jamtvedt, G., Oxman, A. D., Odgaard-Jensen, J., Kristoffersen, D. T., Forsetlund, L., Bainbridge, D., Freemantle, N., Davis, D., et al. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000409.pub2 · Cited by 1,279
Tannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A., & Ahmed, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.949 · Cited by 665
Association of road-traffic accidents with benzodiazepine use
Barbone, F., McMahon, A., Davey, P., Morris, A., Reid, I., McDevitt, D., & MacDonald, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04087-2 · Cited by 559
Benzodiazepine use and risk of dementia: prospective population based study
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.-F., Peres, K., Kurth, T., & Pariente, A. (2012) · BMJ · doi:10.1136/bmj.e6231 · Cited by 436 · cited 1×
“…advocate short-term use of BZDs [2,3] because long-term use leads to tolerance and dependence and is associated with many adverse effects, including somnolence, daytime drowsiness, memory disruption [4–6], increased risk of falls resulting in hip fracture [7–9], and motor vehicle accidents [10,11].”
Hypnotics' association with mortality or cancer: a matched cohort study
Kripke, D. F., Langer, R. D., & Kline, L. E. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-000850 · Cited by 408
Bellolio, M. F., & Stead, L. G. (2009) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2008.05.034 · Cited by 346
Sample Size Calculations for Cluster Randomised Trials
Campbell, M., Grimshaw, J., Steen, N., & Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action) (2000) · Journal of Health Services Research & Policy · doi:10.1177/135581960000500105 · Cited by 298
British National Formulary: BNF
Press, P. (2015) · doi:10.18578/bnf.147942626 · Cited by 269
Newton, M. S., Estabrooks, C. A., Norton, P., Birdsell, J. M., Adewale, A. J., & Thornley, R. (2007) · Implementation Science · doi:10.1186/1748-5908-2-1 · Cited by 264
Weich, S., Pearce, H. L., Croft, P., Singh, S., Crome, I., Bashford, J., & Frisher, M. (2014) · BMJ · doi:10.1136/bmj.g1996 · Cited by 259
Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0174730 · Cited by 225 · cited 1×
“…advocate short-term use of BZDs [2,3] because long-term use leads to tolerance and dependence and is associated with many adverse effects, including somnolence, daytime drowsiness, memory disruption [4–6], increased risk of falls resulting in hip fracture [7–9], and motor vehicle accidents [10,11].”
Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212
Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
Voshaar, R. C. O., Couvée, J. E., Van Balkom, A. J. L. M., Mulder, P. G. H., & Zitman, F. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.189.3.213 · Cited by 205
Benzodiazepine use and cognitive decline in the elderly
Picton, J. D., Marino, A. B., & Nealy, K. L. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160381 · Cited by 203
(2003) · Europe PMC (PubMed Central) · Cited by 176
Pimlott, N., Hux, J. E., Wilson, L., Kahan, M., Li, C., & Rosser, W. (2003) · Europe PMC (PubMed Central) · Cited by 166
Association between Benzodiazepine Use and Dementia: A Meta-Analysis
Zhong, G., Wang, Y., Zhang, Y., & Zhao, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127836 · Cited by 164
Systematic Review of Interventions to Improve Prescribing
Ostini, R., Hegney, D., Jackson, C., Williamson, M., Mackson, J. M., Gurman, K., Hall, W., & Tett, S. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l488 · Cited by 141
Sirdifield, C., Anthierens, S., Creupelandt, H., Chipchase, S. Y., Christiaens, T., & Siriwardena, A. N. (2013) · BMC Family Practice · doi:10.1186/1471-2296-14-191 · Cited by 131
Bakken, M. S., Engeland, A., Engesæter, L. B., Ranhoff, A. H., Hunskaar, S., & Ruths, S. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1684-z · Cited by 125 · cited 1×
“…advocate short-term use of BZDs [2,3] because long-term use leads to tolerance and dependence and is associated with many adverse effects, including somnolence, daytime drowsiness, memory disruption [4–6], increased risk of falls resulting in hip fracture [7–9], and motor vehicle accidents [10,11].”
Vicens, C., Bejarano, F., Sempere, E., Mateu, C., Fiol, F., Socias, I., Aragonès, E., Palop, V., Beltran, J. L., Piñol, J. L., et al. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.134650 · Cited by 122
Self-citationBenzodiazepine-Like Hypnotics and the Associated Risk of Road Traffic Accidents
Orriols, L., Philip, P., Moore, N., Castot, A., Gadegbeku, B., Delorme, B., Mallaret, M., & Lagarde, E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.3 · Cited by 118
Khong, T. P., de Vries, F., Goldenberg, J. S. B., Klungel, O. H., Robinson, N. J., Ibáñez, L., & Petri, H. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9603-8 · Cited by 87
Anthierens, S., Habraken, H., Petrovic, M., & Christiaens, T. (2007) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813430701726335 · Cited by 86
Sirdifield, C., Chipchase, S. Y., Owen, S., & Siriwardena, A. N. (2017) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-016-0182-z · Cited by 81 · cited 3×
“The high variability in prescribing BZDs among practices [21] can be explained local health policies regarding the prescription of BZDs, internal conditions of the healthcare practices, and beliefs and attitudes of the GPs regarding the benefits and risks of BZDs [22–24].”
Airagnes, G., Lemogne, C., Renuy, A., Goldberg, M., Hoertel, N., Roquelaure, Y., Limosin, F., & Zins, M. (2019) · BMC Public Health · doi:10.1186/s12889-019-6933-8 · Cited by 76 · cited 1×
“However, many clinicians overprescribe BZDs and chronic use is common [15,16].”
Lynch, T., Ryan, C., Hughes, C. M., Presseau, J., van Allen, Z. M., Bradley, C. P., & Cadogan, C. A. (2020) · Addiction · doi:10.1111/add.14981 · Cited by 76
Withdrawal from long-term benzodiazepine use: randomised trial in family practice.
(2006) · PubMed Central · Cited by 67
Self-citationClay, E., Falissard, B., Moore, N., & Toumi, M. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1424-1 · Cited by 65 · cited 1×
“Overall number of prescriptions of BZDs and BZD-like drugs (Z-drugs) has modestly decreased over the last 10 years in Europe [17].”
Lasserre, A., Younès, N., Blanchon, T., Cantegreil-Kallen, I., Passerieux, C., Thomas, G., Chan-Chee, C., & Hanslik, T. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x483922 · Cited by 60
Voshaar, R. C. O., Gorgels, W. J., Mol, A. J., van Balkom, A. J., Mulder, J., van de Lisdonk, E. H., Breteler, M. H., & Zitman, F. G. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100706 · Cited by 60
Midlöv, P., Bondesson, Å., Eriksson, T., Nerbrand, C., & Höglund, P. (2005) · Family Practice · doi:10.1093/fampra/cmi105 · Cited by 60
A controlled trial of educational visiting to improve benzodiazepine prescribing in general practice
de Burgh, S., Mant, A., Mattick, R. P., Donnelly, N., Hall, W., & Bridges‐Webb, C. (1995) · Australian Journal of Public Health · doi:10.1111/j.1753-6405.1995.tb00364.x · Cited by 51
Coe, A., Kaylor‐Hughes, C., Fletcher, S. L., Murray, E., & Gunn, J. M. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052547 · Cited by 42 · cited 1×
“The most common deprescribing interventions include the identifying appropriate patients for deprescribing, providing education and development training to the GPs and patients, and using tailored stepped dose reduction of BZDs [35,36].”
Bejarano‐Romero, F., Piñol, J. L., Gilabert, N. M., Luque, P. C., López, N. B., & Basora, J. (2008) · Atención Primaria · doi:10.1016/s0212-6567(08)75695-6 · Cited by 37
Tsimtsiou, Z., Ashworth, M., & Jones, R. (2009) · British Journal of General Practice · doi:10.3399/bjgp09x420923 · Cited by 33 · cited 2×
“The high variability in prescribing BZDs among practices [21] can be explained local health policies regarding the prescription of BZDs, internal conditions of the healthcare practices, and beliefs and attitudes of the GPs regarding the benefits and risks of BZDs [22–24].”
Arana, M. A., Valderas, J. M., & Solomon, J. (2019) · BMC Family Practice · doi:10.1186/s12875-018-0892-5 · Cited by 33
Mokhar, A., Topp, J., Härter, M. C., Schulz, H., Kühn, S., Verthein, U., & Dirmaier, J. (2018) · PeerJ · doi:10.7717/peerj.5535 · Cited by 28
Physicians’ beliefs and attitudes about Benzodiazepines: a cross-sectional study
Neves, I. T., Oliveira, J., Fernandes, M., dos Santos, O. R., & Maria, V. A. J. (2019) · BMC Family Practice · doi:10.1186/s12875-019-0965-0 · Cited by 25 · cited 1×
“The high variability in prescribing BZDs among practices [21] can be explained local health policies regarding the prescription of BZDs, internal conditions of the healthcare practices, and beliefs and attitudes of the GPs regarding the benefits and risks of BZDs [22–24].”
Benzodiazepine prescribing by GP registrars. A trial of educational outreach.
Zwar, N. A., Wolk, J., Gordon, J., & Sanson‐Fisher, R. (2000) · PubMed · Cited by 24
Vicens, C., Leiva, A., Bejarano‐Romero, F., Sempere, E., Rodríguez-Rincón, R. M., Fiol, F., Mengual, M., Ajenjo-Navarro, A., do Pazo-Oubiña, F., Mateu, C., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022046 · Cited by 22 · cited 1×
“The details of the protocol were published elsewhere [44] (S1 Study Protocol).”
Self-citationIntervention against Long-term use of Hypnotics/Sedatives in General Practice
Holm, M. (1990) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813439008994941 · Cited by 18
Mokhar, A., Kühn, S., Topp, J., Dirmaier, J., Härter, M. C., & Verthein, U. (2019) · BJGP Open · doi:10.3399/bjgpopen18x101626 · Cited by 18
Socias, I. M., Leiva, A., Pombo, H., Bejarano‐Romero, F., Verdú, E. S., Rodríguez-Rincón, R. M., Fiol, F., Mengual, M., Ajenjo-Navarro, A., do Pazo-Oubiña, F., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18157964 · Cited by 13
Self-citation
Cited by
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
Persaud, N., Workentin, A., Rizvi, A., Pierson, T., Bortolussi‐Courval, É., Liu, K., Bennett, A., Shaver, N., Skidmore, B., Vyas, N., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17965 · Cited by 31
Zeraatkar, D., Nagraj, S. K., Ling, M., Jassal, T., Kirsh, S., Lima, J. P., Pitre, T., Couban, R., Hussain, M., Seterelv, S. S., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081336 · Cited by 30
Peñarrubia‐María, M. T., Parker, L. A., Puig‐García, M., Fuente‐Moreno, M., Lumbreras, B., López-Pintor, E., Domènech‐Abella, J., Sáez, M., Dima, A. L., Guzmán, A. F., et al. (2025) · Family Medicine and Community Health · doi:10.1136/fmch-2024-003233 · Cited by 8
Paraskevopoulos, A., Wettermark, B., & Tsiligianni, I. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01188-3 · Cited by 4
“A previous study in Spain demonstrated the efficacy of such interventions in decreasing chronic users [54].”
Metadata
- Authors
- Vicens, C., Leiva, A., Bejarano, F., Sempere-Verdú, E., Rodríguez-Rincón, R. M., Fiol, F., Mengual, M., Ajenjo-Navarro, A., Do Pazo, F., Mateu, C., Folch, S., Alegret, S., Coll, J. M., Martín-Rabadán, M., & Socias, I.
- Affiliations
- Health Research Institute of the Balearic Islands (ES)
- Hospital Universitario Son Espases (ES)
- Institut Català de la Salut (ES)
- Conselleria de Sanitat Universal i Salut Pública (ES)
- Hospital Can Misses (ES)
- Corresponding author
- Leiva, Alfonso
- ORCID
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-05-06
- Volume
- 19
- Issue
- 5
- Pages
- e1003983
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC9075619
- OpenAlex
- W4229001905
- Cited by
- 15
- References
- 52
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 1 · 2023: 1
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nc-nd)
- Hispana (submittedVersion, cc-by-nc-nd)
- Funders
- Instituto de Salud Carlos III (PI15/01480)
- Sociedad Española de Medicina Familiar y Comunitaria -semFYC-
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Health Professions › General Health Professions › Health Policy Implementation Science
- Keywords
- benzodiazepine prescribing, overprescribing, general practitioners, tapering, long-term benzodiazepine use, multicomponent intervention, primary care, defined daily doses, older adults, benzodiazepine dependence, health professions education, Spain, Catalonia, Balearic Islands
- MeSH terms
- Aged, Benzodiazepines, Feedback, Female, Humans, Male, Spain, Prescriptions, General Practitioners
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
